银川市苯丙酮尿症患儿苯丙氨酸羟化酶基因突变特征

IF 2 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Xinyou Yu, Fang Liu, Bo Wei, Meijuan Li, Ruiping Lu, Lihua Pan
{"title":"银川市苯丙酮尿症患儿苯丙氨酸羟化酶基因突变特征","authors":"Xinyou Yu,&nbsp;Fang Liu,&nbsp;Bo Wei,&nbsp;Meijuan Li,&nbsp;Ruiping Lu,&nbsp;Lihua Pan","doi":"10.24976/Discov.Med.202335177.54","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Phenylalanine hydroxylase deficiency (PAHD) is an autosomal recessive disorder affecting phenylalanine (Phe) metabolism caused by mutations in the phenylalanine hydroxylase (<i>PAH</i>) gene. It has a complex phenotype with many variants and genotypes in various populations. This study sets out to analyze the screening results of children with phenylketonuria (PKU) in Yinchuan City and characterize the mutation variants of the <i>PAH</i> gene.</p><p><strong>Methods: </strong>Phenylketonuria screening results were retrospectively analyzed in 398,605 neonates (207,361 males and 191,244 females) born in different maternity hospitals in Yinchuan City between January 2017 and December 2021. Screening for genetic metabolic diseases was performed with parental consent at their own expense. A comprehensive diagnosis was performed by integrating tandem mass spectrometry (MS/MS) findings with clinical presentations. High-throughput sequencing (HTS) was used to detect genetic and metabolic disease-associated genes in children with PKU who were clinically diagnosed and voluntarily tested. The identified loci were validated through Sanger sequencing and parental verification.</p><p><strong>Results: </strong>Among the screened newborns, 45 (11.3/100,000) PKU cases were diagnosed. In the 38 cases that underwent self-financed <i>PAH</i> sequencing, 56 mutations were detected in 76 chromosomes, with an overall detection rate of 73.7%. All patients harbored mutant genes, and the 56 mutations detected identified represented 14 variants, including 8 missense mutations, 2 splicing mutations, 2 nonsense mutations, and 2 silent mutations. The mutations were primarily distributed in <i>exons 2</i>, <i>3</i>, <i>6</i>, <i>7</i>, <i>9</i>, <i>11</i>, and <i>intron 4</i>, with the highest frequency observed in <i>exon 7</i> (25 [44.7%]), followed by <i>exon 11</i> (15 [26.7%]). The most prevalent mutations were <i>exon 7</i>-p.R252W (10 [17.9%]) and <i>exon 7</i>-p.R261Q (8 [14.3%]).</p><p><strong>Conclusions: </strong>The <i>PAH</i> gene mutations in children with PKU in Yinchuan City are predominantly concentrated in <i>exons 6</i>, <i>7</i>, and <i>11</i>, with the highest detection rates observed for p.R252W and p.R261Q mutations.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mutation Characteristics of Phenylalanine Hydroxylase Gene in Children with Phenylketonuria in Yinchuan City.\",\"authors\":\"Xinyou Yu,&nbsp;Fang Liu,&nbsp;Bo Wei,&nbsp;Meijuan Li,&nbsp;Ruiping Lu,&nbsp;Lihua Pan\",\"doi\":\"10.24976/Discov.Med.202335177.54\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Phenylalanine hydroxylase deficiency (PAHD) is an autosomal recessive disorder affecting phenylalanine (Phe) metabolism caused by mutations in the phenylalanine hydroxylase (<i>PAH</i>) gene. It has a complex phenotype with many variants and genotypes in various populations. This study sets out to analyze the screening results of children with phenylketonuria (PKU) in Yinchuan City and characterize the mutation variants of the <i>PAH</i> gene.</p><p><strong>Methods: </strong>Phenylketonuria screening results were retrospectively analyzed in 398,605 neonates (207,361 males and 191,244 females) born in different maternity hospitals in Yinchuan City between January 2017 and December 2021. Screening for genetic metabolic diseases was performed with parental consent at their own expense. A comprehensive diagnosis was performed by integrating tandem mass spectrometry (MS/MS) findings with clinical presentations. High-throughput sequencing (HTS) was used to detect genetic and metabolic disease-associated genes in children with PKU who were clinically diagnosed and voluntarily tested. The identified loci were validated through Sanger sequencing and parental verification.</p><p><strong>Results: </strong>Among the screened newborns, 45 (11.3/100,000) PKU cases were diagnosed. In the 38 cases that underwent self-financed <i>PAH</i> sequencing, 56 mutations were detected in 76 chromosomes, with an overall detection rate of 73.7%. All patients harbored mutant genes, and the 56 mutations detected identified represented 14 variants, including 8 missense mutations, 2 splicing mutations, 2 nonsense mutations, and 2 silent mutations. The mutations were primarily distributed in <i>exons 2</i>, <i>3</i>, <i>6</i>, <i>7</i>, <i>9</i>, <i>11</i>, and <i>intron 4</i>, with the highest frequency observed in <i>exon 7</i> (25 [44.7%]), followed by <i>exon 11</i> (15 [26.7%]). The most prevalent mutations were <i>exon 7</i>-p.R252W (10 [17.9%]) and <i>exon 7</i>-p.R261Q (8 [14.3%]).</p><p><strong>Conclusions: </strong>The <i>PAH</i> gene mutations in children with PKU in Yinchuan City are predominantly concentrated in <i>exons 6</i>, <i>7</i>, and <i>11</i>, with the highest detection rates observed for p.R252W and p.R261Q mutations.</p>\",\"PeriodicalId\":11379,\"journal\":{\"name\":\"Discovery medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Discovery medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.24976/Discov.Med.202335177.54\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discovery medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24976/Discov.Med.202335177.54","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:苯丙氨酸羟化酶缺乏症(PAHD)是由苯丙氨酸羟化酶(PAH)基因突变引起的一种影响苯丙氨酸(Phe)代谢的常染色体隐性遗传病。它具有复杂的表型,在不同的人群中具有许多变异和基因型。本研究旨在分析银川市苯丙酮尿症(PKU)患儿的筛查结果,并对PAH基因的突变变异进行表征。方法:回顾性分析2017年1月至2021年12月在银川市不同妇产医院出生的398,605例新生儿(男207,361例,女191,244例)苯丙酮尿筛查结果。遗传代谢疾病的筛查是在父母同意的情况下进行的,费用自理。通过串联质谱(MS/MS)结合临床表现进行全面诊断。采用高通量测序(HTS)检测临床诊断和自愿检测的PKU患儿的遗传和代谢疾病相关基因。鉴定的基因座通过Sanger测序和亲本验证进行验证。结果:在筛查的新生儿中,诊断出45例(11.3/10万)PKU。在38例自费PAH测序的患者中,检测到76条染色体56个突变,总检出率为73.7%。所有患者均携带突变基因,检测到的56个突变代表14个变异,其中8个错义突变,2个剪接突变,2个无义突变,2个沉默突变。突变主要分布在外显子2、3、6、7、9、11和内含子4,其中外显子7频率最高(25[44.7%]),其次是外显子11(15[26.7%])。最普遍的突变是外显子7-p。R252W(10[17.9%])和外显子7-p。R261q(8[14.3%])。结论:银川市PKU患儿PAH基因突变主要集中在6、7、11外显子,其中p.R252W和p.R261Q突变检出率最高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mutation Characteristics of Phenylalanine Hydroxylase Gene in Children with Phenylketonuria in Yinchuan City.

Background: Phenylalanine hydroxylase deficiency (PAHD) is an autosomal recessive disorder affecting phenylalanine (Phe) metabolism caused by mutations in the phenylalanine hydroxylase (PAH) gene. It has a complex phenotype with many variants and genotypes in various populations. This study sets out to analyze the screening results of children with phenylketonuria (PKU) in Yinchuan City and characterize the mutation variants of the PAH gene.

Methods: Phenylketonuria screening results were retrospectively analyzed in 398,605 neonates (207,361 males and 191,244 females) born in different maternity hospitals in Yinchuan City between January 2017 and December 2021. Screening for genetic metabolic diseases was performed with parental consent at their own expense. A comprehensive diagnosis was performed by integrating tandem mass spectrometry (MS/MS) findings with clinical presentations. High-throughput sequencing (HTS) was used to detect genetic and metabolic disease-associated genes in children with PKU who were clinically diagnosed and voluntarily tested. The identified loci were validated through Sanger sequencing and parental verification.

Results: Among the screened newborns, 45 (11.3/100,000) PKU cases were diagnosed. In the 38 cases that underwent self-financed PAH sequencing, 56 mutations were detected in 76 chromosomes, with an overall detection rate of 73.7%. All patients harbored mutant genes, and the 56 mutations detected identified represented 14 variants, including 8 missense mutations, 2 splicing mutations, 2 nonsense mutations, and 2 silent mutations. The mutations were primarily distributed in exons 2, 3, 6, 7, 9, 11, and intron 4, with the highest frequency observed in exon 7 (25 [44.7%]), followed by exon 11 (15 [26.7%]). The most prevalent mutations were exon 7-p.R252W (10 [17.9%]) and exon 7-p.R261Q (8 [14.3%]).

Conclusions: The PAH gene mutations in children with PKU in Yinchuan City are predominantly concentrated in exons 6, 7, and 11, with the highest detection rates observed for p.R252W and p.R261Q mutations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Discovery medicine
Discovery medicine MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
5.40
自引率
0.00%
发文量
80
审稿时长
6-12 weeks
期刊介绍: Discovery Medicine publishes novel, provocative ideas and research findings that challenge conventional notions about disease mechanisms, diagnosis, treatment, or any of the life sciences subjects. It publishes cutting-edge, reliable, and authoritative information in all branches of life sciences but primarily in the following areas: Novel therapies and diagnostics (approved or experimental); innovative ideas, research technologies, and translational research that will give rise to the next generation of new drugs and therapies; breakthrough understanding of mechanism of disease, biology, and physiology; and commercialization of biomedical discoveries pertaining to the development of new drugs, therapies, medical devices, and research technology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信